566 reports of this reaction
2.5% of all ALTEPLASE reports
#9 most reported adverse reaction
HAEMORRHAGE is the #9 most commonly reported adverse reaction for ALTEPLASE, manufactured by Genentech, Inc.. There are 566 FDA adverse event reports linking ALTEPLASE to HAEMORRHAGE. This represents approximately 2.5% of all 22,483 adverse event reports for this drug.
Patients taking ALTEPLASE who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is a less commonly reported adverse event for ALTEPLASE, but still significant enough to appear in the safety profile.
In addition to haemorrhage, the following adverse reactions have been reported for ALTEPLASE:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 566 FDA reports for ALTEPLASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 2.5% of all adverse event reports for ALTEPLASE, making it a notable side effect.
If you experience haemorrhage while taking ALTEPLASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.